14th Nov 2006 07:02
Advanced Medical Solutions Grp PLC14 November 2006 For immediate release 14 November 2006 Advanced Medical Solutions Group plc ("AMS" or "the Company") MULTI-CENTRE CLINICAL EVALUATION OF ACTIVHEAL(R) EQUIVALENT EFFICACY DEMONSTRATED OVER LEADING COMPETITOR PRODUCTS AND SUSTAINED ANTIMICROBIAL ACTIVITY FOR SILVER ALGINATE DRESSINGS Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the globalmedical technology company, announces that new and significant clinical andscientific study findings relating to the effectiveness of AMS' products, andthe resultant substantial time and cost savings to the NHS, will be presentedtoday in two posters at the Wounds UK 2006 Wound Care Conference in Harrogate.The conference is being held from 13-15 November 2006. Findings presented in one poster entitled "A Summary of UK Evaluation of theActivHeal(R) Range of First Line Dressings", confirmed that substantial costsavings to the NHS can be achieved through the use of AMS products. Data frommulti-centre clinical evaluations showed that 98% of ActivHeal(R) woundcareresponses were equivalent to or better than responses from other dressings.Whilst independent laboratory test have previously shown that the ActivHeal(R)range has comparable physical properties to market leaders this new informationstrongly endorses the clinical effectiveness of AMS' products. The study data was collated from more than 150 applications from 9 Trusts,including 5 hospitals and 4 Primary Care Trusts. Savings achieved by using the ActivHeal(R) range as a first line therapy can bemade at a time when there is severe pressure on woundcare budgets, freeing upfunds for treating chronic wounds and for new technologies. ActivHeal(R)consist of alginate, hydrocolloid, hydrogel and foam dressings and is designedto offer cost effective first line treatment of general wounds. The second poster entitled "21 Day InVitro Study of Sustained AntimicrobialActivity of a New Silver Alginate Dressing" relates to a study of theantimicrobial properties of a new AMS silver alginate compared with those of aleading brand in combating a variety of micro-organisms frequently found inwounds, including antibiotic-resistant pathogens, such as MRSA, over an extendedperiod of up to 21 days. This study concluded that both the AMS silver alginate and leading brand wereproven to provide sustained antimicrobial action against the test organisms upto 14 days. After this period, whilst the antimicrobial action of the leadingbrand diminished significantly, the AMS silver alginate continued to kill thetest organisms for up to the 21 day completion of the study. This studyindicates that the AMS silver alginate provides a sustained level ofantimicrobial activity. This, combined with the inherent absorbency of thedressing, may reduce dressing change frequency, and hence minimise pain andtrauma to the patient. The silver alginate reduces the time and overall cost oftreatment and gives a better opportunity for healing to progress undisturbed. Commenting on today's announcement Dr. Don Evans, Chief Executive of AMS,stated: "This new information is of key significance to the business. The multi-centreevaluation confirms that Activheal(R) offers the NHS a cost effective range offirst line woundcare dressings whilst providing comparable or even beneficialclinical performance. The results of this study have enabled clinicians from anumber of the Trusts involved to start using some or all of the dressings fromthe ActivHeal(R) range. AMS now supplies more than 20 hospital trusts and wehope to grow this number further. "The results of the silver alginate study will allow us to strengthen ourmarketing claims for this product and we look forward to progressing thisthrough regulatory approvals. Both of the posters presented in Harrogateunderline AMS' ability to deliver both innovation and cost management solutionsto the woundcare market." Copies of the posters described above are available from the Company's websiteat www.admedsol.com or from Buchanan Communications. -ENDS- For further information, please contact: Advanced Medical Solutions Group plc Tel : +44 (0) 1606 545508Don Evans, Chief ExecutiveMary Tavener, Finance Directorwww.admedsol.com Buchanan Communications Tel: +44 (0) 20 7466 5000Mark Court, Mary-Jane Johnson Notes to Editors: Advanced Medical Solutions is a leading company in the development andmanufacture of products for the $13 billion global woundcare market. Founded in1991 and currently quoted on AIM, Advanced Medical Solutions is focused on thedesign, development and manufacture of innovative and technologically advancedproducts for woundcare and other medical applications. In-house natural and synthetic polymer technology is used to provide advancedwound dressings based on the moist healing principle. AMS's resources ensure aunique position as a vertically integrated 'one stop shop' to provide allcategories of moist wound healing products. The Company has the capability tomove from product design and development through to production and deliveryready for distribution into customer markets. The acquisition of MedLogic in 2002 has brought AMS products and technology incyanoacrylate based tissue adhesives that offer benefits over sutures andstaples for closing wounds sold direct to hospitals or through distributors. AMS's technology and products currently serve the majority of the key globalmarkets and strategic partners. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Advanced Medical Solutions Group